The World Health Organization announced its now recommending GLP-1 drugs, such as Ozempic , Weogvy and Mounjaro, to manage adult obesity on Monday (December 1).

The WHO said the GLP-1 drugs can be used as long-term treatment when combined with healthy diets and physical activity, the latter of which had solely served as the organization's previous recommended focus. The guidelines published in the medical journal JAMA on Monday marked a major shift in how it has historically framed treatment for the chronic disease.

“GLP-1 therapies mark more than a scientific breakthrough,” the officials wrote. “They represent a new chapter in the gradual conceptual shift in how society approaches obesity — from a ‘lifestyle condition’ to a complex, preventable, and treatable chronic disease.”

See Full Page